Monthly information on shares outstanding and voting rights (in French) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Share buyback program (in French) Descriptif du programme de rachat d’actions autorisé par l’assemblée générale mixte des actionnaires du 24 mai 2016 Liquidity contract related information Implementation of the liquidity agreement Half-year report on… Continue reading Regulated information
Category: tools invest
Annual General Meeting
Annual General Meeting of May 15, 2024 2024 ORDINARY AND EXTRAORDINARY MEETING Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE Date and Time 15 May 2024 at 10 am – Retransmission (live and deferred)Webcast link to French language conference callPlease log in to the following link to obtain your personal telephone… Continue reading Annual General Meeting
événements et presentations
Corporate presentation Webcasts Financial calendar Investor events
Analysts
Company Analyst E-mail Phone Cantor Fitzgerald Brandon Folkes brandon.folkes@cantor.com +1 212-294-8081 Intron Health Naresh Chouhan naresh@intronhealthresearch.com +44 207 375 9143 Invest Securities Jamila El Bougrini jelbougrini@invest-securities.com +33 (0)1 44 88 88 09 Kempen & Co. Suzanne van Voorthuizen suzanne.vanvoorthuizen@kempen.com +31 (0)20 348 8484 Oddo BHF Martial Descoutures martial.descoutures@oddo-bhf.com +33 (0)1 44 51 85 00 Any… Continue reading Analysts
General
Stock price Loading… More on Euronext » General Stock Market Euronext Paris – Eurolist (compartiment C) Reuters / Bloomberg TRNG.PA / TNG.FP ISIN Code FR0005175080 Total number of shares outstanding 132,293,932 Initial Public Offering (IPO) March 26, 1998 Local Sector Index Next Biotech Financial Year Ends December 31
Information boursière
Financial information
Financial reports
Years Quarter Interim Registration Document First Second Third Fourth 2024 2023 XBRL(fr) Amendment(fr) 2022 XBRL(fr) 2021 XBRL(fr) 2020 2019 2018 … Continue reading Financial reports
Key figures
In € million except share and per share data 2023 2022 2021 2020 2019 Revenue 7.9 10.3 17.4 9.9 13.7 R&D Expense -29.6 -32.2 -32.9 -27.3 -31.4 G&A Expense -7.0 -7.9 -7.4 -6.5 -7.1 Net income (loss) -22.3 -32.8 -19.5 -17.2 -18.8 Net Cash Burn -24.0 -22.8 -10.0 -17.0 -20.5 Cash & Cash Equivalents 15.7… Continue reading Key figures
